Psychedelic Medicine Now Has a Calendar

Psychedelic medicine has moved from an open-ended scientific theme to a sector with identifiable clinical, regulatory and commercialization milestones, but approval will not immediately ensure patient access.

• Compass Pathways has reported positive Phase 3 results for COMP360 in treatment-resistant depression and expects to complete its rolling NDA submission in Q4 2026, with a potential commercial launch in the first half of 2027 subject to FDA approval and DEA rescheduling.
• The late-stage pipeline spans Usona’s Phase 3 psilocybin program, Definium’s DT120 program with a generalized-anxiety readout expected in September 2026, Otsuka/Transcend’s approximately 300-patient Phase 3 PTSD trial, and other programs involving MDMA and 5-MeO-DMT.
• An April 2026 executive order supports priority vouchers, research coordination and product-specific rescheduling after successful Phase 3 trials and FDA approval, while psilocybin, MDMA, LSD and ibogaine remain Schedule I.
• The FDA awarded three National Priority Vouchers to programs from Compass Pathways, Usona Institute and Transcend Therapeutics; the vouchers may shorten review timelines but do not change safety, efficacy or manufacturing standards.
• Funding is concentrating in later-stage companies: psychedelic companies raised more than $1 billion in Q2 2026, while the VA is running 20 active psychedelic-therapy trials and its PIVOT study will enroll roughly 240 veterans across five sites through June 2031.
• Oregon recorded 5,375 supervised psilocybin administration sessions for 5,935 clients in 2025, illustrating the operational requirements that may also affect future FDA-approved treatments.

Takeaway: Investors should track each company’s trial readouts, NDA filing, FDA review, DEA rescheduling and delivery infrastructure separately, because clinical approval, commercial availability and scalable access will occur on different timelines.